Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Denise Fabian, Maria del Pilar Guillermo Prieto Eibl, Iyad Alnahhas, Nikhil Sebastian, Pierre Giglio, Vinay Puduvalli, Javier Gonzalez, Joshua D. Palmer

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations


Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

Original languageEnglish (US)
Article number174
Issue number2
StatePublished - Feb 2019
Externally publishedYes


  • GBM
  • Glioblastoma
  • TTF
  • Tumor treating fields

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review'. Together they form a unique fingerprint.

Cite this